Impact du vaccin antiméningococcique C conjugué en Espagne : une décision épidémiologique et microbiologique
R. Cano(Instituto de Salud Carlos III), Julio A. Vázquez(Nuffield Health), C. Salcedo(Instituto de Salud Carlos III), Amparo Larrauri(Instituto de Salud Carlos III), Sergio Herrera, B. Alcalá(Instituto de Salud Carlos III)
Cited by 0
Related Papers
First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020
|Eurosurveillance|2020|715
Estimates of Pandemic Influenza Vaccine Effectiveness in Europe, 2009–2010: Results of Influenza Monitoring Vaccine Effectiveness in Europe (I-MOVE) Multicentre Case-Control Study
|PLoS Medicine|2011|303
Excess all-cause mortality during the COVID-19 pandemic in Europe – preliminary pooled estimates from the EuroMOMO network, March to April 2020
|Eurosurveillance|2020|238